Changes in Hong Kong stocks | Conoa-B (02162) rose nearly 7%, foreign cooperation and commercial sales, two-wheel drive sales, and is expected to turn a loss into a profit in the first half of the year

The Zhitong Finance App learned that Conoa-B (02162) rose nearly 7%. As of press release, it had risen 6.8% to HK$87.2, with a turnover of HK$179 million.

According to the news, Conoah announced a few days ago that it is expected to make a profit of not less than RMB 1.2 billion in the first half of 2026, while the loss for the same period last year was about RMB 79 million. The conversion of loss into profit during the period was mainly due to the fact that the Group had received a total down payment of US$257 million in the second quarter of 2026, which was recognized as other income during the reporting period, approximately RMB 1.68 billion; KYM Biosciences Inc., a non-wholly-owned subsidiary of the Group with 70% interest, and AstraZeneca initiated research and completed the first case of patient administration, triggering related milestone payments. This milestone payment was recognized as cooperative revenue during the reporting period, approximately RMB 220 million.

In addition, the company's innovative product Kangyueda® has outstanding clinical value, and the number of patients covered continues to increase. In the first half of 2026, it achieved sales revenue of 390 million yuan, an increase of 132% over the previous year, providing the company with continuous revenue. Huayuan Securities previously stated that considering the company's commercialization volume can be expected, BD earnings are expected to gradually be realized as the commercialization process continues to advance, maintaining a “buy” rating.